Athersys (NASDAQ:ATHX) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX) in a research report issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Shares of ATHX opened at $0.01 on Friday. The company has a 50 day moving average price of $0.01 and a 200-day moving average price of $0.05. Athersys has a fifty-two week low of $0.01 and a fifty-two week high of $1.99. The stock has a market capitalization of $370,314.00, a PE ratio of 0.00 and a beta of -0.90.

Institutional Investors Weigh In On Athersys

Several hedge funds have recently modified their holdings of ATHX. Vanguard Group Inc. lifted its position in Athersys by 9.0% during the first quarter. Vanguard Group Inc. now owns 10,986,945 shares of the biopharmaceutical company’s stock valued at $6,652,000 after acquiring an additional 910,501 shares during the last quarter. State Street Corp lifted its position in Athersys by 5.6% during the first quarter. State Street Corp now owns 3,781,384 shares of the biopharmaceutical company’s stock valued at $2,290,000 after acquiring an additional 201,070 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Athersys by 37.6% during the second quarter. JPMorgan Chase & Co. now owns 3,155,103 shares of the biopharmaceutical company’s stock valued at $820,000 after acquiring an additional 861,475 shares during the last quarter. Millennium Management LLC lifted its position in Athersys by 381.8% during the second quarter. Millennium Management LLC now owns 2,317,856 shares of the biopharmaceutical company’s stock valued at $603,000 after acquiring an additional 1,836,746 shares during the last quarter. Finally, UBS Group AG lifted its position in Athersys by 30.1% during the second quarter. UBS Group AG now owns 724,652 shares of the biopharmaceutical company’s stock valued at $188,000 after acquiring an additional 167,756 shares during the last quarter. Hedge funds and other institutional investors own 19.35% of the company’s stock.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.